Market Place
Sourcing Support
IntelGenx Updates On Previously Announced Sale And Investment Process
19 Jul 2024 //
GLOBENEWSWIRE
IntelGenx Reports Preliminary Results For Montelukast VersaFilm In Alzheimer`s
03 Jul 2024 //
GLOBENEWSWIRE
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
11 Jun 2024 //
PRESS RELEASE
IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
28 May 2024 //
GLOBENEWSWIRE
IntelGenx Initiates CCAA Proceedings For Strategic Review
17 May 2024 //
GLOBENEWSWIRE
IntelGenx Announces Voting Results on Election of Directors
08 May 2024 //
GLOBENEWSWIRE
IntelGenx Announces First Parkinson`s Disease Patients Dosed in Phase 2 Trial
08 Apr 2024 //
GLOBENEWSWIRE
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
05 Apr 2024 //
GLOBENEWSWIRE
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
IntelGenx Enters Into a Third Amended Agreement atai Life Sciences
11 Mar 2024 //
PRESS RELEASE
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With ATAI Life
11 Mar 2024 //
GLOBENEWSWIRE
Studies Validate Advantages Administering Drugs to Pets via IntelGenx’s VetaFilm
05 Feb 2024 //
PRESS RELEASE
Studies Validate Advantages of Administering Drugs to Pets
05 Feb 2024 //
GLOBENEWSWIRE
IntelGenx Announces New Animal Health Partnership
18 Dec 2023 //
GLOBENEWSWIRE
IntelGenx Announces Closing of Subsequent Non-Brokered Private Placement
05 Dec 2023 //
GLOBENEWSWIRE
IntelGenx Announces Shareholder Approval of Financing Transactions
28 Nov 2023 //
GLOBENEWSWIRE
IntelGenx Receives Approval to Conduct MONTPARK Montelukast VersaFilm Ph 2 Trial
14 Nov 2023 //
GLOBENEWSWIRE
IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting
13 Nov 2023 //
GLOBENEWSWIRE
IntelGenx Reports First Agreement for CDMO Packaging Services
08 Nov 2023 //
CONTRACT PHARMA
IntelGenx Announces Commercialization of Cannabinoid-Infused VersaFilm
06 Nov 2023 //
GLOBENEWSWIRE
IntelGenx to Report Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
IntelGenx Provides RIZAFILM® U.S. Commercialization Update
21 Sep 2023 //
GLOBENEWSWIRE
IntelGenx Provides Regulatory Update for Buprenorphine Buccal Film
19 Sep 2023 //
GLOBENEWSWIRE
IntelGenx Announces Closing of First Tranche Non-Brokered From Strategic Partner
31 Aug 2023 //
GLOBENEWSWIRE
IntelGenx Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
IntelGenx Announces First Agreement for CDMO Packaging Services
10 Aug 2023 //
GLOBENEWSWIRE
IntelGenx to Report Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
IntelGenx Completes Enrollment for ˜BUENA™ Montelukast VersaFilm® Phase 2a Trial
01 Aug 2023 //
GLOBENEWSWIRE
IntelGenx Provides Update on Collaboration Evaluating Montelukast VersaFilm
25 Jul 2023 //
GLOBENEWSWIRE
IntelGenx Announces a Change to its Board of Directors
21 Jul 2023 //
GLOBENEWSWIRE
IntelGenx Announces Voting Results on Election of Directors
06 Jul 2023 //
GLOBENEWSWIRE
IntelGenx Unveils Short-Term Commercial Objectives
31 May 2023 //
GLOBENEWSWIRE
IntelGenx Receives Amended DEL License to Conduct Third-Party Testing
17 May 2023 //
GLOBENEWSWIRE
IntelGenx Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
IntelGenx to Report 1Q 2023 FYR on May 11, 2023 €“ Conference Call to Follow
04 May 2023 //
GLOBENEWSWIRE
IntelGenx Announces Receipt of CRL from the FDA for Xiromed Buprenorphine
27 Apr 2023 //
GLOBENEWSWIRE
IntelGenx Extends Period to Exercise Certain Warrants
27 Apr 2023 //
GLOBENEWSWIRE
IntelGenx Announces FDA Approval of RIZAFILM for Treatment of Acute Migraine
18 Apr 2023 //
BIOSPACE
IntelGenx Announces Organizational Changes to Support Global Growth Strategy
13 Apr 2023 //
GLOBENEWSWIRE
IntelGenx Reports Fourth Quarter and Full-Year 2022 Financial Results
29 Mar 2023 //
GLOBENEWSWIRE
IntelGenx Revises Fourth Quarter and Full Year 2022 Financial Results Reporting
24 Mar 2023 //
GLOBENEWSWIRE
IntelGenx to Report Fourth Quarter and Full Year 2022 Financial Results
23 Mar 2023 //
GLOBENEWSWIRE
IntelGenx Announces Closing of Notes Offering
21 Mar 2023 //
GLOBENEWSWIRE
IntelGenx to Participate in the 35th Annual Roth Conference
09 Mar 2023 //
GLOBENEWSWIRE
IntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Patent
21 Feb 2023 //
GLOBENEWSWIRE
IntelGenx Announces Collaboration with Neurologist for Montelukast VersaFilm
09 Feb 2023 //
GLOBENEWSWIRE
IntelGenx & Arwan Enter into a Supply Agreement for RIZAPORT® in MENA Countries
23 Jan 2023 //
GLOBENEWSWIRE
IntelGenx Receives Fourth and Final Loan Tranche from atai
09 Jan 2023 //
GLOBENEWSWIRE
IntelGenx Receives FDA PDUFA Date for RIZAFILM®
22 Nov 2022 //
GLOBENEWSWIRE
IntelGenx Reschedules 3Q 2022 Conference Call Due to Technical Issues
10 Nov 2022 //
GLOBENEWSWIRE
IntelGenx Enters into Feasibility & Develop Agreement For CBD-Infused VetaFilm™
09 Nov 2022 //
GLOBENEWSWIRE
IntelGenx Files Provisional U.S. Patent Application for Oral Film Formulation
02 Nov 2022 //
GLOBENEWSWIRE
IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate
25 Oct 2022 //
GLOBENEWSWIRE
After rejections, IntelGenx shares migraine film data with FDA
25 Oct 2022 //
FIERCEPHARMA
IntelGenx Announces Issuance of New U.S. Patent Covering VersaFilm® Technology
20 Oct 2022 //
GLOBENEWSWIRE
IntelGenx Submits Response to CRL from FDA for RIZAPORT® VersaFilm®
19 Oct 2022 //
GLOBENEWSWIRE
IntelGenx’s Collaboration with atai Life Sciences Culminates For Clinical Study
13 Oct 2022 //
GLOBENEWSWIRE
IntelGenx Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
GLOBENEWSWIRE
IntelGenx Completes Share Issuance in Payment of Principal and Interest on Debt
05 Jul 2022 //
GLOBENEWSWIRE
IntelGenx Announces Intention to Issue Shares on Outstanding Debentures
01 Jun 2022 //
GLOBENEWSWIRE
